Our system is currently under heavy load due to increased usage. We're actively working on upgrades to improve performance. Thank you for your patience.
2022
DOI: 10.1002/adma.202200254
|View full text |Cite
|
Sign up to set email alerts
|

A Readily Scalable, Clinically Demonstrated, Antibiofouling Zwitterionic Surface Treatment for Implantable Medical Devices

Abstract: conditions to maintain the scale of medical device manufacturing; and 4) the treatment must not incorporate antibiotics to maintain global antimicrobial stewardship efforts. The zwitterionic polymer polysulfobetaine (PSB) was selected as the antifouling component of the surface modification to benefit from its biocompatibility, ultralow-fouling properties, and oxidative stability. By adsorbing water electrostatically, PSB coatings form a thin hydration barrier that prevents organic materials from adhering to s… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
30
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 24 publications
(31 citation statements)
references
References 63 publications
1
30
0
Order By: Relevance
“…32 BoNT-A has become a mainstay of NLUTD management since its introduction in the early 2000s and approval by the U.S. Food and Drug Administration for this indication in 2011. 33 However, the costs associated with BoNT-A management remain high while this treatment is inaccessible in low-income countries. Even in high-income countries included in this analysis, BoNT-A therapy costs can amount to ECONOMIC BURDEN OF NEUROGENIC LOWER URINARY TRACT DYSFUNCTION $7,060 per patient per year.…”
Section: Discussionmentioning
confidence: 99%
“…32 BoNT-A has become a mainstay of NLUTD management since its introduction in the early 2000s and approval by the U.S. Food and Drug Administration for this indication in 2011. 33 However, the costs associated with BoNT-A management remain high while this treatment is inaccessible in low-income countries. Even in high-income countries included in this analysis, BoNT-A therapy costs can amount to ECONOMIC BURDEN OF NEUROGENIC LOWER URINARY TRACT DYSFUNCTION $7,060 per patient per year.…”
Section: Discussionmentioning
confidence: 99%
“…In general, cell adhesion to hydrophobic surfaces has been previously described by McVerry et al as due to the nonpolar nature of PDMS and the significant increase in antibacterial effect when its surface is modified to hydrophilic 15 . As the surface of PUR is naturally hydrophobic 34 but less hydrophobic than silicone, bacterial adhesion and growth in the surrounding medium are expected when there is a possibility to use the material's surface for attachment and multiplication.…”
Section: Figure 1 the Variations In E Coli Concentrations In The Grow...mentioning
confidence: 99%
“…Also, grafting acrylates 7 to silicone rubber (Pseudomonas, catheter) effectively suppresses non-specific protein adsorption and cell adhesion, suppressing hydrophobic recovery of the surface. One of the most recent works by McVerry et al shows a successful one-step hydrophilic surface modification in ambient conditions and under UV light to create a zwitterionic polymer polysulfobetaine and perfluorophenylazide network onto silicone surface 15 . The reported antibacterial activity was due to the formation of the surface hydration layer in the presence of the hydrophilic coating.…”
Section: Introductionmentioning
confidence: 99%
“…These formed scars can encapsulate the implant surface and cause recording/ stimulation performance degradation over time. 14 To solve this issue, various surface coatings have been developed to minimize protein adsorption and biofouling at material's surfaces (Table S1), 15,16 devices. 17 Nevertheless, PEG gel suffers from hydrolysis and oxidative degradation and enzymatic cleavage during in vivo applications.…”
Section: ■ Introductionmentioning
confidence: 99%